Skip to main content
OpenTrials
Completed

NCT Number: NCT02179749

Mifepristone Treatment of Alcohol Use Disorder

This is an 8-week, randomized, double-blind, placebo-controlled, 2 arm, parallel groups, study of 1-week of treatment with mifepristone (0, 1200 mg/d) given in conjunction with 8 weeks of manual-guided counseling, and a follow-up visit at Week 12.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The Scripps Research Institute

La Jolla, California, 92037, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female volunteers, 18-65 years of age
  • Meets Diagnostic and Statistical Manual (DSM)-V criteria for current alcohol use disorder of moderate or greater severity, defined by DSM-V as ≥ 4 symptoms
  • Abstinent a minimum of 3 days (but not more than 30 days) prior to randomization
  • In acceptable health in the judgment of the study physician, on the basis of interview, medical history, physical exam, ECG, urine test and lab tests
  • Females with childbearing potential must have a negative serum pregnancy test on the screening visit and a negative urine pregnancy test at randomization and agree to use non-hormonal effective birth control for the study duration and one month thereafter

Exclusion criteria

  • A medical condition or chronic use of a medication that contraindicates the administration of mifepristone
  • Significant medical disorders or clinically significant findings on ECG (e.g., prolongation of the corrected QT interval,urine or blood tests that increase potential risk or interfere with study participation as determined by the Study Physician. Note: serum potassium below the normal range must be replaced to normal prior to randomization; individuals with serum potassium outside the range of normal will not be randomized
  • Liver function tests more than 3 times the upper limit of normal or elevated bilirubin
  • Female subjects with childbearing potential who are pregnant, nursing, or refuse to use effective non hormonal birth control for the 1-week of medication administration and one month thereafter
  • Meets Diagnostic and Statistical Manual -V criteria for a major Axis I disorder including mood or anxiety disorders or substance use disorders other than alcohol or nicotine use disorders

Treatment and study plan

Mifepristone 1200 mg daily

Drug

Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.

Other names: Korlym

Standardized behavioral therapy

Behavioral

Standardized behavioral therapy 1 time per week for 8 week duration.

Other names: Manually-guided therapy

Placebo

Drug

Placebo tablets, Four tablets daily/am for 1-week duration.

Other names: Placebo Comparator

Primary outcomes

  1. Drinking Quantity Per Day

    Time frame: Participants will be followed for up to 12 weeks post-assignment

    Drinking quantity in standard drinks per day is measured by the Timeline Followback interview.

    A standard drink contains 14 grams of alcohol, e.g., 1.5 ounces of distilled spirits, 5 ounces of wine, or 12 ounces of beer.

Secondary outcomes

  1. Craving

    Time frame: Participants will be followed for up to 12 weeks

    Alcohol Craving Questionnaire; minimum value equals 12, maximum value equals 84; higher scores mean greater craving for alcohol.

Sponsors and collaborators

Lead sponsor

The Scripps Research Institute

Other

Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Registry information

Official study title

Glucocorticoid Antagonist Treatment of Alcohol Use Disorder

Important dates

Study start
2014
Primary completion
2019
Study completion
2019
First posted
Jul 2, 2014
Registry last updated
Oct 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.